Pain Management
Page 1 • 2 itemsGain critical insights into the global pain management drug market. Discover pipeline updates, regulatory shifts, and investment opportunities.
Contineum Therapeutics PIPE-791 Shows Positive Phase 1b Results for Chronic Osteoarthritis Pain
Contineum Therapeutics reports positive Phase 1b trial data for PIPE-791, a non-opioid LPA1 receptor antagonist for chronic osteoarthritis pain treatment.
Dogwood Therapeutics SP16 Gets FDA IND Approval for Chemotherapy-Induced Pain Treatment
Dogwood Therapeutics receives FDA IND acceptance for SP16, a non-opioid IV treatment targeting chemotherapy-induced pain and neuropathy in cancer patients.